Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k)... ( VANCOUVER April 17 / Angiotech Ph...)

Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k) clearance

Date:4/17/2008

VANCOUVER, April 17 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its innovative 5-Fluorouracil-coated (5-FU) Central Venous Catheter (CVC) in the United States.

"The 5-FU CVC represents our first drug-eluting medical device product to be researched and developed completely in-house by Angiotech's R & D and clinical teams, without the aid of a corporate partner," said Dr. William Hunter, President and CEO of Angiotech. "This is an important milestone in our Company's history, and we look forward to moving into the commercial phase of our 5-FU CVC product, as well as developing other implantable devices that utilize this novel and proprietary anti-infective technology platform."

The clinical data from Angiotech's 960 patient clinical trial comparing its 5-FU CVC with a chlorhexidine/silver sulfadiazine (CH-SS) coated CVC was recently presented by clinical investigators at the 28th International Symposium on Intensive Care and Emergency Medicine in Brussels. The study met its primary non-inferiority endpoint and there were no occurrences of clinically evident blood stream infection in patients treated with Angiotech's 5-FU CVC.

About Angiotech's 5-FU CVC

Angiotech has demonstrated that 5-FU, a well-known and FDA approved drug, has effectively demonstrated its ability to prevent catheter-related infections as compared with CH-SS coated catheters. In addition, since 5-FU is not routinely used as either a systemic antibiotic or a hospital antiseptic, there may be a reduced risk to the hospital or the communi
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
2. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
3. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
4. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
5. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
6. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
7. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
8. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
9. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
10. ReachBio Partners with Axiogenesis to Distribute Novel Cell-Based Products in North America
11. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology

Post Your Comments:

Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k)...( VANCOUVER April 17 / Angiotech Ph...)